Filter
163
Filtered Results: 163
Text search:
antiepileptic
drugs
Featured
Recommendations
25
New Publications
31
Language
Document type
No document type
124
Guidelines
20
Studies & Reports
9
Manuals
7
Fact sheets
2
Strategic & Response Plan
1
Countries / Regions
India
10
Nepal
6
Africa
4
Latin America and the Carribbean
4
South Africa
4
Uganda
4
Ethiopia
4
Kenya
3
Rwanda
2
Malawi
2
Zimbabwe
2
Philippines
2
Global
2
Zambia
2
South Sudan
2
Eswatini/ Swaziland
2
Ukraine
1
Ghana
1
Sierra Leone
1
China
1
Syria
1
Nigeria
1
Afghanistan
1
Germany
1
Congo, Democratic Republic of
1
Middle East and North Africa
1
South–East Asia Region
1
Western and Central Europe
1
Paraguay
1
Argentina
1
Eastern Europe
1
Brazil
1
Russia
1
Bhutan
1
Botswana
1
Indonesia
1
Liberia
1
Authors & Publishers
Publication Years
Category
Countries
46
Clinical Guidelines
14
Women & Child Health
7
Capacity Building
3
Public Health
3
Key Resources
3
Toolboxes
Mental Health
77
Disability
15
Pharmacy
14
TB
4
COVID-19
4
NTDs
2
AMR
2
Refugee
1
Caregiver
1
NCDs
1
Q8. Should Anti-Epileptic Drug (AED) treatment be started after first unprovoked seizure in non-specialist health settings?
Q12: Should the treatment be similar in individuals with intellectual disability and epilepsy compared to people with epilepsy only?
Q 7: For adults and children with convulsive epilepsy, which standard antiepileptic drugs (phenobarbital, phenytoin, carbamazepine, valproic acid) when compared to placebo/a comparator produce benefits/harm in the specified outcomes?
Q9. In adults and children with convulsive epilepsy in remission, when should treatment be discontinued?
Q 10: In adults and children with epilepsy, which psychological interventions used as adjunctive therapies with antiepileptic drugs when compared to placebo/comparator produce benefits/harm in specified outcomes?
The internationally recognized criteria for diagnosis of neurocysticercosis include a requirement for neuroimaging techniques, such as computerized tomography (CT) and/or magnetic resonance imaging (MRI), ideally supported by serology. These facilities are not available in all settings, especially i...
This is the fifteenth edition of the lecture notes. They were first published in 1987 as a summary of the material used in the biannual epilepsy teaching weekend organised under the auspices of the UK Chapter of the International League against Epilepsy.
(Lecture series consist of a total of 59 cha...
Scoping Question: For adults and children living with HIV, which antiepileptic medications (such as phenobarbital, phenytoin, carbamazepine or valproic acid) produce benefits and/or harms when compared to a placebo or controls?
SCOPING QUESTION: For adults and children with medication-resistant convulsive epilepsy, which anti-epileptic medications produce benefits and/or harm in the specified outcomes when compared to a placebo or a comparator?
Second Edition, 2012
SCOPING QUESTION: In adults with established status epilepticus (i.e., seizures persisting after the first-line treatment with benzodiazepines [or benzodiazepines-resistant status epilepticus]), which anti-epileptic medications are associated with cessation of seizures and reduced adverse effects)?
...
3rd edition
[Updated 2015]
Scoping Question: In adults with acute convulsive seizures in first-level care or in the community (when no IV access is available), which antiepileptic medications produce benefits and/or harm when compared to comparator?
Guidelines for treatment of drug-susceptible tuberculosis and patient care
Uptsate 2017
SCOPING QUESTION: In adults with acute convulsive seizures, where intravenous access is available, which first-line anti- epileptic medication should be used to abort seizures when compared to comparator?
Low- and middle-income countries (LMICs) experience a high disease burden for epilepsy, a chronic neurological condition.The authors evaluate the cost-effectiveness of community health workers (CHWs) to improve adherence to medication for epilepsy in South Africa. They found that utilizing CHWs to i...
6th edition, The NLEM 2021 contains 398 drugs molecules in different therapeutic categories.
